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YEAR IN CARDIOLOGY SERIESAYEAR IN CARDIOLOGY SERIES359Year in Heart FailureAnjali Tiku Owens, Mariell Jessup
Owens and Jessup review last year’s literature for the most compelling articles pertaining to
the broad field of heart failure. Epidemiology, risk profiling and prevention, biomarkers,
pathophysiology, transplant, and mechanical support are some of the main topics covered.CLINICAL RESEARCH INTERVENTIONAL CARDIOLOGY
369bciximab and UFH Superior to Bivalrudin for
NSTEMI Patients With High On-Treatment Platelet ReactivityDirk Sibbing, Isabell Bernlochner, Stefanie Schulz, Steffen Massberg, Albert Schömig, Julinda Mehilli,
Adnan Kastrati
The ISAR-REACT 4 platelet substudy sought to determine the relevance of high on-
clopidogrel treatment platelet reactivity (HPR) in non–ST-segment elevation myocardial
infarction (NSTEMI) patients treated with abciximab and unfractionated heparin (UFH) or
bivalirudin during percutaneous coronary intervention (PCI). The presence or absence of
HPR following clopidogrel loading (600 mg) was determined by platelet function testing on a
multiplate analyzer. For abciximab with UFH, there was no difference in the efficacy endpoint
(30-day incidence of death, myocardial infarction, or urgent target vessel revascularization)
between HPR and no-HPR patients (9.4% vs. 6.7%, odds ratio [OR]: 1.4). For bivalirudin,
the incidence of the efficacy endpoint was significantly higher in HPR patients (22% vs. 5.0%,
OR: 5.4). The impact of HPR on clinical outcomes may depend on the type of adjunctive
antithrombotic therapy used during PCI.
Editorial Comment: Germano Di Sciascio, Fabio Mangiacapra, p. 378(continued on page A-18)
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Cornelis Jan de Vries, Adrianus J. van Boven
In this randomized trial a first-generation sirolimus-eluting stent (SES) was compared with a
second-generation everolimus-eluting stent (EES) in patients with acute myocardial infarction
(AMI) undergoing primary percutaneous coronary intervention (PCI). A total of 625 patients
were randomized in the XAMI (Xience vs. Cypher in AMI) trial that was powered for
noninferiority in the primary endpoint, which was the occurrence of cardiac death, nonfatal
AMI, or any target vessel revascularization (TVR) in the first year. The major adverse cardiac
event rate was 4.0% for EES and 7.7% for SES, which was significantly lower. The rates of
cardiac mortality and definite and/or probable stent thrombosis were both low and not
statistically different, although both favored EES. This trial shows that this EES is
noninferior, and probably superior, to this SES for AMI.CARDIAC SURGERY
388igher Chest Tube Output, Lower Mortality in CABG Patients
Previously Treated With Prasugrel Than ClopidogrelPeter K. Smith, Lawrence T. Goodnough, Jerrold H. Levy, Robert S. Poston, Mary A. Short,
Govinda J. Weerakkody, LeRoy A. LeNarz
Smith and colleagues used data from the TRITON–TIMI 38 (Trial to Assess Improvement
in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel–Thrombolysis In
Myocardial Infarction 38) trial, which randomized acute coronary syndrome patients to
clopidogrel or prasugrel to characterize the bleeding, transfusion requirements, and clinical
outcomes of patients who subsequently underwent coronary artery bypass grafting (CABG).
A significantly higher mean 12-h chest tube blood loss was observed with prasugrel compared
with clopidogrel, but there was not a significant difference in red blood cell transfusions. All-
cause 30-day mortality was significantly lower with prasugrel compared with clopidogrel.
Despite an increase in bleeding and surgical re-exploration for bleeding, prasugrel was
associated with a lower risk of death following CABG compared with clopidogrel.(continued on page A-21)
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EVASCULAR DISEASE397Aneurysms-Osteoarthritis Syndrome Patients at High Risk for Aortic DissectionDenise van der Linde, Ingrid M. B. H. van de Laar, Aida M. Bertoli-Avella, Rogier A. Oldenburg,
Jos A. Bekkers, Francesco U. S. Mattace-Raso, Anton H. van den Meiracker, Adriaan Moelker,
Fop van Kooten, Ingrid M. E. Frohn-Mulder, Janneke Timmermans, Els Moltzer, Jan M. Cobben,
Lut van Laer, Bart Loeys, Julie De Backer, Paul J. Coucke, Anne De Paepe, Yvonne Hilhorst-Hofstee,
Marja W. Wessels, Jolien W. Roos-Hesselink
Aneurysms-osteoarthritis syndrome (AOS) is a recently described autosomal dominant
connective tissue disorder characterized by aneurysms, dissections, and tortuosity throughout
the arterial tree in combination with osteoarthritis and mild craniofacial features. It is caused
by pathogenic SMAD3 variants. van der Linde and colleagues describe the cardiovascular
henotype of AOS found in 44 patients from 7 families. An aortic root aneurysm was found
n three-quarters of patients. Many also had cerebrovascular abnormalities. The main cause of
eath was aortic dissection (9 of 15; 60%). AOS predisposes patients to aggressive and
idespread cardiovascular disease, and is associated with high mortality mostly due to aortic
issections.ditorial Comment: Eloisa Arbustini, Nupoor Narula, p. 404IMAGING IN HEART RHYTHM DISORDERS408High Risk of Ventricular Arrhythmia When >5% of Left Ventricle Is Scar TissueIgor Klem, Jonathan W. Weinsaft, Tristram D. Bahnson, Don Hegland, Han W. Kim, Brenda Hayes,
Michele A. Parker, Robert M. Judd, Raymond J. Kim
Current sudden cardiac death (SCD) risk stratification algorithms emphasize left-ventricular
ejection fraction (LVEF), however, better algorithms are needed. Klem and colleagues
reviewed cardiac magnetic resonance (CMR) images from 137 patients undergoing evaluation
for possible implantable cardioverter-defibrillator placement. The rate of adverse events
steadily increased with decreasing LVEF. On the other hand, there was a sharp step-up in
risk for scar size 5% of LV mass (hazard ratio: 5.2) compared with 5%. Patients with
VEF 30% and significant scarring had similar risk to patients with LVEF 30%.
yocardial scarring detected by CMR is an independent predictor of the risk of SCD.
ditorial Comment: Nathan Mewton, Philippe Chevalier, p. 421(continued on page A-22)
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Ng and colleagues tested the hypothesis that “virtual” electrophysiologic studies (EPS) on an
anatomic platform generated by 3-dimensional (3D) magnetic resonance imaging (MRI)
reconstruction of the left ventricle (LV) could identify the re-entrant circuits of induced
ventricular tachycardia (VT) after myocardial infarction (MI). MI by coronary artery occlusion
was induced in 8 pigs. 3D cardiac MRIs were obtained from each pig. Normal areas, gray
zones, and infarct cores were identified with gray zones assigned slower conduction and
longer action potential durations in the computer model. Six of the seven pigs that developed
VT during actual EPS were also inducible with virtual EPS with similar VT circuit locations.
This study demonstrates the feasibility of applying a mathematical model to MRI
reconstructions of the LV to predict VT circuits.
